FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Haviland Kate
2. Issuer Name and Ticker or Trading Symbol

Blueprint Medicines Corp [ BPMC ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Operating Officer
(Last)          (First)          (Middle)

C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET
3. Date of Earliest Transaction (MM/DD/YYYY)

12/13/2021
(Street)

CAMBRIDGE, MA 02139
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/13/2021  M(1)  1000 A$36.05 54948 D  
Common Stock 12/13/2021  S(1)  285 D$99.65 (2)54663 D  
Common Stock 12/13/2021  S(1)  210 D$98.50 (3)54453 D  
Common Stock 12/13/2021  S(1)  411 D$97.60 (4)54042 D  
Common Stock 12/13/2021  S(1)  94 D$96.78 (5)53948 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $36.05 12/13/2021  M (1)    1000   (6)2/16/2027 Common Stock 1000 $0 591 D  

Explanation of Responses:
(1) Effected pursuant to a trading plan adopted on January 12, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
(2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.99 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) in this form 4.
(3) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.02 to $98.98 per share.
(4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.99 to $97.98 per share.
(5) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.98 per share.
(6) This option was granted on February 16, 2017 and is fully vested as of the date hereof.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Haviland Kate
C/O BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET
CAMBRIDGE, MA 02139


Chief Operating Officer

Signatures
/s/ Ariel Hurley, Attorney-in-Fact12/15/2021
**Signature of Reporting PersonDate

Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Blueprint Medicines Charts.